Heteroplasmy Shifting as Therapy for Mitochondrial Disorders

Area of Science:

• Genetics
• Molecular Biology
• Cellular Biology

Background:

• Mitochondrial diseases result from pathogenic mitochondrial DNA (mtDNA) variants, leading to cellular energy deficits.
• These disorders are often fatal, with no current treatments targeting the root cause.
• Pathogenic mtDNA variants exist as heteroplasmy, where the ratio of pathogenic to wild-type mtDNA influences disease onset and severity.

Purpose of the Study:

• To review current techniques for preventing pathogenic mtDNA inheritance through mitochondrial replacement therapy (MRT).
• To explore strategies for shifting heteroplasmy in individuals with active mitochondrial disease.
• To highlight the urgent need for clinical translation of these promising therapeutic approaches.

Main Methods:

• Mitochondrial Replacement Therapy (MRT): Creating embryos with parental nuclear DNA and donor wild-type mtDNA to avoid maternal pathogenic variants.
• Heteroplasmy Shifting Strategies: Categorized into nuclease-dependent and nuclease-independent approaches to alter the pathogenic mtDNA load in affected individuals.
• Review of existing research in mouse models and patient-derived cells.

Main Results:

• MRT aims to prevent transmission of pathogenic mtDNA mutations to offspring.
• Heteroplasmy shifting strategies show promise in preclinical studies for reducing pathogenic mtDNA levels.
• Despite initial successes, these techniques are not yet in clinical use.

Conclusions:

• Developing effective treatments for mitochondrial diseases is critical due to their severity and lack of current therapeutic options.
• Mitochondrial replacement therapy and heteroplasmy shifting represent potential avenues for preventing and treating mitochondrial disorders.
• Urgent translational research is required to bring these novel strategies from the lab to the clinic.